Literature DB >> 2510141

Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity.

A Haj-Yehia1, M Bialer.   

Abstract

The following valpromide (VPD) derivatives were synthesized and their structure-pharmacokinetic relationships explored: ethylbutylacetamide (EBD), methylpentylacetamide (MPD), propylisopropylacetamide (PID), and propylallylacetamide (PAD). In addition, the anticonvulsant activity of these compounds was evaluated and compared to that of VPD, valnoctamide (VCD), and valproic acid (VPA). MPD, the least-branched compound had the largest clearance and shortest half-life of all the amides investigated and was the least active. All other amides had similar pharmacokinetic parameters. Unlike the other amides, PID and VCD did not metabolize to their respective homologous acids and were the most active compounds. Our study showed that these amides need an unsubstituted beta position in their aliphatic side chain in order to biotransform to their homologous acids. An amide which is not metabolized is more potent as an anticonvulsant than its biotransformed isomer. All amides were more active than their respective homologous acids. In this particular series of aliphatic amides, which were derived from short-branched fatty acids, the anticonvulsant activity was affected by the pharmacokinetics in general and by the biotransformation of the amide to its homologous acid in particular. This amide-acid biotransformation appeared to be dependent upon the chemical structure, especially upon the substitution at position beta of the molecule.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2510141     DOI: 10.1023/a:1015934321764

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  25 in total

1.  A clinical study in the use of valmethamide, an anxiety-reducing drug.

Authors:  W STEPANSKY
Journal:  Curr Ther Res Clin Exp       Date:  1960-05

2.  Sodium valproate and valpromide: differential interactions with carbamazepine in epileptic patients.

Authors:  F Pisani; A Fazio; G Oteri; C Ruello; C Gitto; F Russo; E Perucca
Journal:  Epilepsia       Date:  1986 Sep-Oct       Impact factor: 5.864

3.  Valpromide but not sodium hydrogen divalproate inhibits epoxide hydrolase in human liver.

Authors:  G M Pacifici; A Rane
Journal:  Pharmacol Toxicol       Date:  1987-03

4.  Possible hazard of valpromide-carbamazepine combination therapy in epilepsy.

Authors:  J W Meijer; C D Binnie; R M Debets; J A van Parys; N K de Beer-Pawlikowski
Journal:  Lancet       Date:  1984-04-07       Impact factor: 79.321

5.  Valpromide/carbamazepine and risk of teratogenicity.

Authors:  G M Pacifici; T Tomson; L Bertilsson; A Rane
Journal:  Lancet       Date:  1985-02-16       Impact factor: 79.321

Review 6.  Suicidal destruction of cytochrome P-450 during oxidative drug metabolism.

Authors:  P R Oritz de Montellano; M A Correia
Journal:  Annu Rev Pharmacol Toxicol       Date:  1983       Impact factor: 13.820

7.  The antiepileptic properties of N-dipropylacetamide (depamide): a clinical trial.

Authors:  R Musolino; G Gallitto; L Morgante; F Pisani; R Di Perri
Journal:  Acta Neurol (Napoli)       Date:  1980-04

8.  Statistical moments in pharmacokinetics.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

9.  Variability in level-dose ratio of valproate: monotherapy versus polytherapy.

Authors:  R H Levy
Journal:  Epilepsia       Date:  1984       Impact factor: 5.864

10.  Increased dipropylacetic acid bioavailability from dipropylacetamide by food.

Authors:  F Pisani; A A D'Agostino; A Fazio; G Oteri; G Primerano; R Di Perri
Journal:  Epilepsia       Date:  1982-04       Impact factor: 5.864

View more
  19 in total

1.  Multivariate statistics of disposition pharmacokinetic parameters for structurally unrelated drugs used in therapeutics.

Authors:  Vangelis Karalis; Anna Tsantili-Kakoulidou; Panos Macheras
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

2.  Pharmacokinetic analysis and antiepileptic activity of tetra-methylcyclopropane analogues of valpromide.

Authors:  M Bialer; S Hadad; B Kadry; A Abdul-Hai; A Haj-Yehia; J Sterling; Y Herzig; B Yagen
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

3.  Theoretical characterization of SOME amides and esters DERIVATIVES of valproic acid.

Authors:  Nieves C Comelli; Patricio Fuentealba; Eduardo A Castro; Alicia H Jubert
Journal:  J Mol Model       Date:  2009-07-16       Impact factor: 1.810

4.  Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain.

Authors:  Ilan Winkler; Simcha Blotnik; Jakob Shimshoni; Boris Yagen; Marshall Devor; Meir Bialer
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

5.  Valnoctamide, a non-teratogenic amide derivative of valproic acid, inhibits arachidonic acid activation in vitro by recombinant acyl-CoA synthetase-4.

Authors:  Hiren R Modi; Mireille Basselin; Stanley I Rapoport
Journal:  Bipolar Disord       Date:  2014-07-08       Impact factor: 6.744

6.  Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects.

Authors:  M Bialer; A Haj-Yehia; N Barzaghi; F Pisani; E Perucca
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 7.  Valproic Acid: second generation.

Authors:  Meir Bialer; Boris Yagen
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

8.  Propylisopropylacetic acid (PIA), a constitutional isomer of valproic acid, uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: a potential drug for bipolar disorder.

Authors:  Hiren R Modi; Mireille Basselin; Ameer Y Taha; Lei O Li; Rosalind A Coleman; Meir Bialer; Stanley I Rapoport
Journal:  Biochim Biophys Acta       Date:  2013-01-23

9.  Pharmacokinetic analysis of the structural requirements for forming "stable" analogues of valpromide.

Authors:  A Haj-Yehia; S Hadad; M Bialer
Journal:  Pharm Res       Date:  1992-08       Impact factor: 4.200

Review 10.  Can we develop improved derivatives of valproic acid?

Authors:  M Bialer; A Haj-Yehia; K Badir; S Hadad
Journal:  Pharm World Sci       Date:  1994-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.